The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review

Surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) chemotherapy is the current standard treatment for glioblastoma multiforme (GBM). The present metaanalysis investigated the impact of prolonged TMZ maintenance therapy (more than 6 cycles) in comparison with standard...

Full description

Saved in:
Bibliographic Details
Published in:Oncology reviews 2020-02, Vol.14 (1), p.461-461
Main Authors: Alimohammadi, Ehsan, Bagheri, Seyed Reza, Taheri, Shahram, Dayani, Maliheh, Abdi, Alireza
Format: Article
Language:English
Subjects:
Bias
Brain cancer
Chemotherapy
FDA approval
Glioblastoma multiforme
Medical prognosis
Meta-analysis
overall survival
Patients
progression free survival
Radiation therapy
Review
temozolomide
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) chemotherapy is the current standard treatment for glioblastoma multiforme (GBM). The present metaanalysis investigated the impact of prolonged TMZ maintenance therapy (more than 6 cycles) in comparison with standard TMZ maintenance therapy (exactly six cycles) on overall survival (OS) and progression-free survival (PFS) of patients with GBM. A meta-analysis of the literature was conducted using Medline, PubMed, EMBASE and the Cochrane Library in accordance with PRISMA guidelines. Seven articles involving 1018 patients were included. The overall survival was higher in the case group (>6 cycles TMZ) compared to the control group (6 cycles TMZ) (Z=2.375, P=0.018). The lower and upper limits were between 1.002-10.467 months. The case group had higher progression-free survival compared with the control group (Z=3.84; P
ISSN:1970-5565
1970-5557
1970-5565
1970-5557
DOI:10.4081/oncol.2020.461